Nottingham, UK – April 13, 2015 – Molecular Profiles has announced that the company is to adopt Juniper Pharma Services as its new brand name from April 13th 2015.
The move has coincided with its Boston-based parent company Columbia Laboratories, Inc. adopting its new brand identity as Juniper Pharmaceuticals, Inc., effective Monday, April 13, 2015, on which date its common stock began trading on the Nasdaq Stock Exchange under the new ticker symbol — “JNP”.
A new corporate website, reflecting the Juniper brand identity, has been launched at www.juniperpharma.com
Nikin Patel, president at Juniper Pharma Services, said: “The single Juniper brand formalizes the experience and capabilities that have been built in Boston and Nottingham. The name change also coincides with the expansion of our service offering to the North American market.
“As we move forward under the Juniper brand, we remain committed to addressing the needs and challenges of the companies that rely on our contract pharmaceutical development and manufacturing services.”
Juniper Pharma Services assists clients by giving them a solid understanding of their compounds and formulation options. This helps minimise risk of failure during clinical development while ensuring a robust and scalable process is in place.
The contract development and manufacturing organisation (CDMO) specialises in advanced characterisation, IP consulting, formulation development, analytical services and clinical manufacturing.
The science-led manufacturer has well established tableting and capsule filling capabilities focused on delivering product supply for small scale early trials up to Phase III and the rebranding initiative coincides with increased demand for topical and oral dosage form products.
Its new logo includes an icon featuring two interlocked rings, which symbolise the synergies between Juniper’s proprietary women’s health R&D program and contract pharmaceutical development expertise at Juniper Pharma Services.
About Juniper Pharma Services
Juniper Pharma Services Ltd., a wholly owned subsidiary of Juniper Pharmaceuticals, Inc., is a contract development and manufacturing organisation (CDMO) that specializes in pharmaceutical development and production. Its early phase services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist knowledge on developing challenging molecules and complex compounds. Juniper Pharma Services is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company’s services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe. For more information please visit www.juniperpharma.com